Assenagon Asset Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-57,128
| Closed | -$30.6K | – | 1374 |
|
|
2024
Q4 | $30.6K | Sell |
57,128
-387,057
| -87% | -$270K | ﹤0.01% | 1303 |
|
|
2024
Q3 | $782K | Buy |
444,185
+183,396
| +70% | +$256K | ﹤0.01% | 1173 |
|
|
2024
Q2 | $305K | Sell |
260,789
-10,368
| -4% | -$25.9K | ﹤0.01% | 1324 |
|
|
2024
Q1 | $2.45M | Hold |
271,157
| – | – | 0.01% | 817 |
|
|
2023
Q4 | $2.95M | Sell |
271,157
-240,036
| -47% | -$1.8M | 0.01% | 789 |
|
|
2023
Q3 | $4.12M | Sell |
511,193
-171,298
| -25% | -$1.42M | 0.01% | 626 |
|
|
2023
Q2 | $7.41M | Hold |
682,491
| – | – | 0.03% | 414 |
|
|
2023
Q1 | $4.71M | Buy |
682,491
+232,543
| +52% | +$1.46M | 0.02% | 595 |
|
|
2022
Q4 | $1.79M | Sell |
449,948
-77,977
| -15% | -$383K | 0.01% | 849 |
|
|
2022
Q3 | $3.51M | Buy |
527,925
+420,802
| +393% | +$2.59M | 0.01% | 563 |
|
|
2022
Q2 | $518K | Buy |
+107,123
| New | +$652K | ﹤0.01% | 1220 |
|
|
2022
Q1 | – | Sell |
-84,402
| Closed | -$1M | – | 1589 |
|
|
2021
Q4 | $1M | Sell |
84,402
-7,699
| -8% | -$88.9K | ﹤0.01% | 1032 |
|
|
2021
Q3 | $1.05M | Hold |
92,101
| – | – | ﹤0.01% | 897 |
|
|
2021
Q2 | $1.65M | Hold |
92,101
| – | – | 0.01% | 748 |
|
|
2021
Q1 | $1.43M | Hold |
92,101
| – | – | 0.01% | 804 |
|
|
2020
Q4 | $1.12M | Hold |
92,101
| – | – | ﹤0.01% | 712 |
|
|
2020
Q3 | $1.18M | Buy |
+92,101
| New | +$795K | 0.01% | 746 |
|
Assenagon Asset Management's MRNS Position: Q1 2025 in Review
Assenagon Asset Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 57,128 shares — an estimated $30.6K sold.
Assenagon Asset Management first reported a position in MRNS in Q3 2020 and held it in 17 quarters. The position peaked at $7.41M in Q2 2023. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- Assenagon Asset Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- Assenagon Asset Management sold 57,128 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $30.6K.
- Assenagon Asset Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2020 and held it in 17 quarters.
- Assenagon Asset Management's Marinus Pharmaceuticals, Inc position peaked at $7.41M in Q2 2023.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on Assenagon Asset Management's 13F filing for Q1 2025, filed 15 Apr 2025.